[go: up one dir, main page]

NO970786L - Fremgangsmåte for hemming av benprotesedegradering - Google Patents

Fremgangsmåte for hemming av benprotesedegradering

Info

Publication number
NO970786L
NO970786L NO970786A NO970786A NO970786L NO 970786 L NO970786 L NO 970786L NO 970786 A NO970786 A NO 970786A NO 970786 A NO970786 A NO 970786A NO 970786 L NO970786 L NO 970786L
Authority
NO
Norway
Prior art keywords
inhibiting bone
procedure
bone degradation
hexamethylenimino
piperidino
Prior art date
Application number
NO970786A
Other languages
English (en)
Other versions
NO970786D0 (no
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO970786D0 publication Critical patent/NO970786D0/no
Publication of NO970786L publication Critical patent/NO970786L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Fremgangsmåte for hemming av benprotesedegenerering omfattende administrering til et menneske som trenger dette, en effektiv mengde av en forbidnelse med formel (I), a) hvor R' og r3 uavhengig er hydrogen, -CH3, (a) eller (b), hvor Ar eventuelt er substituert med fenyl; R^ er valgt fra gruppen omfattende pyrrolidin, heksametylenimino og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO970786A 1994-08-22 1997-02-20 Fremgangsmåte for hemming av benprotesedegradering NO970786L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/294,170 US5550123A (en) 1994-08-22 1994-08-22 Methods for inhibiting bone prosthesis degeneration
PCT/US1995/010616 WO1996005824A1 (en) 1994-08-22 1995-08-21 Methods for inhibiting bone prosthesis degeneration

Publications (2)

Publication Number Publication Date
NO970786D0 NO970786D0 (no) 1997-02-20
NO970786L true NO970786L (no) 1997-02-20

Family

ID=23132213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970786A NO970786L (no) 1994-08-22 1997-02-20 Fremgangsmåte for hemming av benprotesedegradering

Country Status (18)

Country Link
US (1) US5550123A (no)
EP (1) EP0769944A4 (no)
JP (1) JPH10504576A (no)
KR (1) KR970705384A (no)
CN (1) CN1076968C (no)
AU (1) AU701789B2 (no)
CA (1) CA2198118A1 (no)
CZ (1) CZ52097A3 (no)
FI (1) FI970714A (no)
HU (1) HUT76825A (no)
IL (1) IL115021A (no)
MX (1) MX9701334A (no)
MY (1) MY132085A (no)
NO (1) NO970786L (no)
NZ (1) NZ292013A (no)
UA (1) UA26204C2 (no)
WO (1) WO1996005824A1 (no)
ZA (1) ZA956990B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
AU2001271784A1 (en) * 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
US8403037B2 (en) 2009-12-08 2013-03-26 Baker Hughes Incorporated Dissolvable tool and method
US9079246B2 (en) 2009-12-08 2015-07-14 Baker Hughes Incorporated Method of making a nanomatrix powder metal compact
US9101978B2 (en) 2002-12-08 2015-08-11 Baker Hughes Incorporated Nanomatrix powder metal compact
US9227243B2 (en) 2009-12-08 2016-01-05 Baker Hughes Incorporated Method of making a powder metal compact
US8776884B2 (en) 2010-08-09 2014-07-15 Baker Hughes Incorporated Formation treatment system and method
US9139928B2 (en) 2011-06-17 2015-09-22 Baker Hughes Incorporated Corrodible downhole article and method of removing the article from downhole environment
US9057242B2 (en) 2011-08-05 2015-06-16 Baker Hughes Incorporated Method of controlling corrosion rate in downhole article, and downhole article having controlled corrosion rate
US9033055B2 (en) 2011-08-17 2015-05-19 Baker Hughes Incorporated Selectively degradable passage restriction and method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US441868A (en) * 1890-12-02 Mechanical power
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
NO970786D0 (no) 1997-02-20
ZA956990B (en) 1997-02-21
CN1156406A (zh) 1997-08-06
NZ292013A (en) 2000-07-28
MX9701334A (es) 1997-05-31
UA26204C2 (uk) 1999-07-19
WO1996005824A1 (en) 1996-02-29
CN1076968C (zh) 2002-01-02
JPH10504576A (ja) 1998-05-06
CA2198118A1 (en) 1996-02-29
IL115021A (en) 2000-06-29
AU701789B2 (en) 1999-02-04
KR970705384A (ko) 1997-10-09
EP0769944A1 (en) 1997-05-02
IL115021A0 (en) 1995-12-08
CZ52097A3 (en) 1997-08-13
FI970714A0 (fi) 1997-02-20
MY132085A (en) 2007-09-28
AU3369595A (en) 1996-03-14
US5550123A (en) 1996-08-27
EP0769944A4 (en) 1998-12-30
FI970714A (fi) 1997-02-20
HUT76825A (en) 1997-11-28

Similar Documents

Publication Publication Date Title
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
IL111284A (en) 2-phenyl-3-aroylbenzothiophenes for use as medicaments for inhibiting endometriosis
GR3033269T3 (en) Methods of inhibiting viral replication
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
PH31620A (en) Benzothiophenes for bone healing and fracture repair.
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO983453L (no) Fremgangsmåte for ökning av sfinkterfunksjon
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
DK0771201T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application